Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in Advanced Solid Tumors with DNA Damage Response Gene Aberrations
NCT04550494Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2021
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in solid tumor, sponsored by National Cancer Institute. Started Apr 2021; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04550494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550494.